Items tagged with Drug-resistant TB
Critical Path Institute and TGen forge partnership to advance TB research (post)
TUCSON and FLAGSTAFF, Ariz., May 1, 2017 — The Critical Path to TB Drug Regimens (CPTR), an initiative of the Critical Path Institute (C-Path), has received a $1.1 million grant from the Bill & Melinda Gates Foundation to significantly enrich its Relational Sequencing TB Data Platform (ReSeqTB). To this end, C-Path and the Translational Genomics Research Institute (TGen) are excited to announce a new partnership to sequence at least 12,000 tuberculosis (TB) bacteria isolates from around the world.
New report shows drug-resistant TB set to increase in four high burden countries (post)
Over the next 20 years, cases of drug-resistant tuberculosis (TB) are set to rise in India, the Philippines, Russia, and South Africa - the four countries which already bear the highest burden.
Later-generation fluoroquinolones more effective at reducing mortality risk in resistant TB (post)
Later-generation fluoroquinolones significantly reduced the risk for mortality in patients with suspected drug-resistant tuberculosis compared with early-generation drugs of the same family, according to researchers.
TB bacteria evolve at alarming rate (post)
Researchers from the Vavilov Institute of General Genetics of the Russian Academy of Sciences (VIGG) and the Moscow Institute of Physics and Technology (MIPT) have established a catalog of mutations in 319 virulence genes of mycobacteria that cause tuberculosis. These genes encode proteins that suppress human immune response. Further analysis identified a set of three mutations which may enable mycobacteria to develop rapidly in an immunocompromised environment. The emerging strains of TB pathogens require new treatment approaches including the development of new genetically engineered vaccines that take into account both the immune status of a patient and the specific virulence features of a pathogen. The article was published in Genome Biology and Evolution (Oxford University Press, UK).
Directly observed therapy for multidrug-resistant TB decreases mortality (post)
ATS 2017, WASHINGTON, DC ─ Directly observed therapy (DOT) for multidrug-resistant tuberculosis (MDR-TB) was associated with a 77 percent decrease in mortality in the United States, compared to self-administered therapy from 1993 to 2013, according to new research presented at the ATS 2017 International Conference.
Population implications of the use of bedaquiline in people with extensively drug-resistant TB: are fears of resistance justified? (post)
Summary
Fighting multidrug-resistant TB in Georgia (post)
Institute of Tropical Medicine Antwerp and others to assist the government of Georgia in developing a provider incentive payment scheme for TB.
Page 42 of 117 · Total posts: 0
←First 41 42 43 Last→